Cite
A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis.
MLA
Chung, Melody P., et al. “A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Systemic Sclerosis.” Rheumatology (Oxford, England), vol. 61, no. 6, May 2022, pp. 2441–49. EBSCOhost, https://doi.org/10.1093/rheumatology/keab810.
APA
Chung, M. P., Valenzuela, A., Li, S., Catanese, B., Stevens, K., Fiorentino, D., Strand, V., & Chung, L. (2022). A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. Rheumatology (Oxford, England), 61(6), 2441–2449. https://doi.org/10.1093/rheumatology/keab810
Chicago
Chung, Melody P, Antonia Valenzuela, Shufeng Li, Benjamin Catanese, Kate Stevens, David Fiorentino, Vibeke Strand, and Lorinda Chung. 2022. “A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Systemic Sclerosis.” Rheumatology (Oxford, England) 61 (6): 2441–49. doi:10.1093/rheumatology/keab810.